IP Library Granted Patent US 7,700,102
Granted Patent B2
US 7,700,102 · App. 10/320,769 · Granted Apr 20, 2010

Nucleic acids encoding CD100 molecules

Assignees: Dana-Farber Cancer Institute; Institut National de la Sante et de la Recherche Medicale (INSERM)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,102
App. No.
10/320,769
Granted
Apr 20, 2010
Kind
B2
Abstract

Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferation are disclosed. These novel molecules have a certain homology to semaphorins, proteins which are growth cone guidance molecules that are critical for guiding growing axons of neurons to their targets. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated CD100 proteins, fusion proteins and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Claims (6)

1. A method for inhibiting a B cell response, said method comprising contacting a population of B cells with an antibody to CD100, wherein said antibody binds CD100 and inhibits a CD100 ligand-associated signal, wherein said B cell response is differentiation of a B cell.

2. The method of claim 1 , wherein said antibody is a monoclonal antibody.

3. The method of claim 2 , wherein said monoclonal antibody is a humanized antibody.

4. A method for inhibiting a B cell response in a subject, said method comprising administering to said subject a composition comprising an antibody to CD100, wherein said antibody binds CD100 and inhibits a CD100 ligand-associated signal, wherein said B cell response is differentiation of a B cell.

5. The method of claim 4 , wherein said antibody is a monoclonal antibody.

6. The method of claim 5 , wherein said monoclonal antibody is a humanized antibody.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 16, 2019
From: DANA-FARBER CANCER INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 050078/0303 →
CHANGE OF ADDRESS Recorded Apr 30, 2009
From: CHRONOLOGIC PTY LTD
To: CHRONOLOGIC PTY LTD
Reel/Frame 022621/0701 →
Continuity (2)
Continuation 0855642200 · Nov 9, 1995
Related Publication 20030158402A1 · Aug 21, 2003